Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

ASCEND investigators

Research output: Contribution to journal › Article › peer-review

225 Scopus citations

Fingerprint

Dive into the research topics of 'Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension'. Together they form a unique fingerprint.

Medicine & Life Sciences